<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2022-1-94-99</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group></article-categories><title-group><article-title>Сердечно-сосудистые заболевания у пациентов с псориазом в клинической практике: клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular diseases in patients with psoriasis in clinical practice: case report. Eurasian heart journal</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9240-9513</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmina</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>  Кузьмина Ольга Александровна, аспирант кафедры факультетской терапии №1 Института клинической медицины им. Н. В. Склифосовского</p><p>тел.: 8(499) 248-64-79</p><p>Трубецкая ул., 8, стр. 2, Москва, 119991 </p></bio><bio xml:lang="en"><p> Olga A. Kuzmina, postgraduate student of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of ClinicalMedicine</p><p> tel.: 8(499) 248-64-79 </p><p> 8, building 2, Trubetskaya st., Moscow, 119991 </p></bio><email xlink:type="simple">OLGA.DM.RU@MAIL.RU</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5820-1759</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миронова</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mironova</surname><given-names>O. Iu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>  Миронова Ольга Юрьевна, к.м.н., доц. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского </p><p>Трубецкая ул., 8, стр. 2, Москва, 119991 </p></bio><bio xml:lang="en"><p>  Olga Iu. Mironova, Cand. of Sci. (Med.), Associate Professor of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine </p><p>8, building 2, Trubetskaya st., Moscow, 119991 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>  Фомин Виктор Викторович, чл.-корр. РАН, д.м.н., проф., проректор по инноваицонной и клинической деятельности, зав. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского </p><p>Трубецкая ул., 8, стр. 2, Москва, 119991 </p></bio><bio xml:lang="en"><p>  Viktor V. Fomin, corresponding member of RAS, Dr. of Sci. (Med.), Prof., Vice-Rector for Innovation and Clinical Activities, Head of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine </p><p>8, building 2, Trubetskaya st., Moscow, 119991 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовскии Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>09</day><month>03</month><year>2022</year></pub-date><volume>0</volume><issue>1</issue><fpage>94</fpage><lpage>99</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузьмина О.А., Миронова О.Ю., Фомин В.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Кузьмина О.А., Миронова О.Ю., Фомин В.В.</copyright-holder><copyright-holder xml:lang="en">Kuzmina O.A., Mironova O.I., Fomin V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6307">https://www.heartj.asia/jour/article/view/6307</self-uri><abstract><p>Псориаз является генетически детерминированным заболеванием мультифакториальной природы, которое поражает около 2% популяции. Согласно современным представлениям о данной патологии, высок уровень коморбидных заболеваний, особенно связанных с поражением сердечно-сосудистой системы. В данной статье представлен клинический случай тяжелого течения распространенного вульгарного псориаза, прогрессирующей стадии, смешанной формы у пациентки с очень высоким сердечно-сосудистым риском. Уникальность данного клинического случая заключается в сочетанном течении псориаза и таких коморбидных заболеваний как: гипертоническая болезнь 2 стадии 3 степени повышения АД, очень высокого риска, ожирение 3 степени, дислипидемия, сахарный диабет (СД) 2 типа, гиперурикемия. Основные клинические проявления заключались в наличии распространенных высыпаний на коже пациентки, эпизодов дискомфорта за грудиной при физической нагрузке, а также дестабилизации цифр артериального давления (максимальный подъем до 180/100 мм. рт. ст.). В рамках госпитализации в кожную клинику, пациентке была проведена местная мазевая терапия с применением глюкокортикоидных мазей, мазей, содержащих салициловую кислоту, ПУВА – терапия, по результатам которой со стороны кожного процесса отмечалась положительная динамика в виде регресса высыпаний на 90-100% с исходом в остаточную гиперпигментацию, новых высыпаний отмечено не было. При госпитализации на базе терапевтического стационара, была подобрана оптимальная антигипертензивная, липидснижающая, урикозурическая, гипогликемическая терапия, по результатам которой удалось достигнуть улучшения состояния пациентки, стабилизации цифр артериального давления на уровне 130-140/70 мм. рт. ст. Таким образом, пациенты с псориазом требуют тщательной оценки сердечно-сосудистого риска в клинической практике. Применение мультидисциплинарного подхода позволит не только улучшить качество жизни пациентов, уменьшить вероятность развития крупных сердечно-сосудистых событий, но и увеличить продолжительность жизни, уменьшить смертность.</p></abstract><trans-abstract xml:lang="en"><p>Psoriasis is a genetically determined multifactorial disease that affects about 2% of the population. According to modern concepts of this disease, the level of comorbid diseases, especially those associated with damage to the cardiovascular system, is high. This article presents a clinical case of severe disseminated psoriasis vulgaris, progressive stage, mixed form in a patient with a very high cardiovascular risk. The uniqueness of this clinical case lies in the combined course of psoriasis and such comorbid diseases as: severe hypertension, obesity, dyslipidemia, type 2 diabetes mellitus (DM), hyperuricemia. The main clinical manifestations were the presence of widespread lesions on the patient’s skin, episodes of discomfort behind the sternum during physical activity, as well as destabilization of blood pressure numbers (maximum rise to 180/100 mm Hg). As part of the hospitalization in the skin clinic, the patient underwent topical ointment therapy with the use of glucocorticoid ointments, ointments containing salicylic acid, PUVA therapy, as a result of which the skin process showed positive dynamics with regression of lesions by 90-100% with an outcome in residual hyperpigmentation, no new lesions were noted. During hospitalization to a therapy department, the optimal antihypertensive, lipid-lowering, uricosuric, hypoglycemic therapy was selected, as a result of which it was possible to achieve an improvement in the patient’s condition, stabilization of blood pressure at the level of 130-140/70 mm Hg. So patients with psoriasis require careful assessment of cardiovascular risk in clinical practice. A multidisciplinary approach will not only improve the quality of life of patients, reduce the likelihood of major cardiovascular events, but also increase life expectancy and reduce mortality.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>инфаркт миокарда</kwd><kwd>инсульт</kwd><kwd>гипертоническая болезнь</kwd><kwd>клинический случай</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>cardiovascular risk</kwd><kwd>cardiovascular disease</kwd><kwd>myocardial infarction</kwd><kwd>stroke</kwd><kwd>hypertension</kwd><kwd>case report</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. Journal of the American Academy of Dermatology 2013; 69:1014–1024, https://doi.org/10.1016/J.JAAD.2013.06.053</mixed-citation><mixed-citation xml:lang="en">Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. Journal of the American Academy of Dermatology 2013; 69:1014–1024, https://doi.org/10.1016/J.JAAD.2013.06.053</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study on behalf of the Global Psoriasis Atlas. BMJ 2020;369:m1590, https://doi.org/10.1136/bmj.m1590</mixed-citation><mixed-citation xml:lang="en">Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study on behalf of the Global Psoriasis Atlas. BMJ 2020;369:m1590, https://doi.org/10.1136/bmj.m1590</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician 2017; 63: 278–285.</mixed-citation><mixed-citation xml:lang="en">Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician 2017; 63: 278–285.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology 2017; 76:377–390, https://doi.org/10.1016/J.JAAD.2016.07.064</mixed-citation><mixed-citation xml:lang="en">Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology 2017; 76:377–390, https://doi.org/10.1016/J.JAAD.2016.07.064</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences 2019; 20:1475, https://doi.org/10.3390/ijms20061475</mixed-citation><mixed-citation xml:lang="en">Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences 2019; 20:1475, https://doi.org/10.3390/ijms20061475</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Nehring P, Przybyłkowski A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease? Pharmaceutical Medicine 2020; 34:257–262, https://doi.org/10.1007/s40290-020-00340-1</mixed-citation><mixed-citation xml:lang="en">Nehring P, Przybyłkowski A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease? Pharmaceutical Medicine 2020; 34:257–262, https://doi.org/10.1007/s40290-020-00340-1</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Abramczyk R, Queller JN, Rachfal AW, et al. Diabetes and Psoriasis: Different Sides of the Same Prism. DMSO 2020:13 3571–3577, https://doi.org/10.2147/DMSO.S273147</mixed-citation><mixed-citation xml:lang="en">Abramczyk R, Queller JN, Rachfal AW, et al. Diabetes and Psoriasis: Different Sides of the Same Prism. DMSO 2020:13 3571–3577, https://doi.org/10.2147/DMSO.S273147</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radical Biology and Medicine 2019; 144:266–278, https://doi.org/10.1016/J.FREERADBIOMED.2019.03.036</mixed-citation><mixed-citation xml:lang="en">Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radical Biology and Medicine 2019; 144:266–278, https://doi.org/10.1016/J.FREERADBIOMED.2019.03.036</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Weber B, Merola JF, Husni ME, et al. Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. Current Atherosclerosis Reports 2021; 23:67, https://doi.org/10.1007/s11883-021-00963-y</mixed-citation><mixed-citation xml:lang="en">Weber B, Merola JF, Husni ME, et al. Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. Current Atherosclerosis Reports 2021; 23:67, https://doi.org/10.1007/s11883-021-00963-y</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and MetaAnalysis of Observational Studies, Journal of the American Heart Association, 2013;2:e000062, https://doi.org/10.1161/JAHA.113.000062</mixed-citation><mixed-citation xml:lang="en">Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and MetaAnalysis of Observational Studies, Journal of the American Heart Association, 2013;2:e000062, https://doi.org/10.1161/JAHA.113.000062</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Takeshita J, Grewal S, Langan M, et al. Psoriasis and comorbid diseases Implications for management. Journal of American Dermatology 2017; 76:393–403, https://doi.org/10.1016/j.jaad.2016.07.065</mixed-citation><mixed-citation xml:lang="en">Takeshita J, Grewal S, Langan M, et al. Psoriasis and comorbid diseases Implications for management. Journal of American Dermatology 2017; 76:393–403, https://doi.org/10.1016/j.jaad.2016.07.065</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Masson Martín Lobo Graciela Molinero W. Psoriasis and Cardiovascular Risk: A Comprehensive Review. https://doi.org/10.6084/m9.figshare.12091383</mixed-citation><mixed-citation xml:lang="en">Masson Martín Lobo Graciela Molinero W. Psoriasis and Cardiovascular Risk: A Comprehensive Review. https://doi.org/10.6084/m9.figshare.12091383</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. Journal of the American Academy of Dermatology 2004; 51:563–569, https://doi.org/10.1016/j.jaad.2004.04.012</mixed-citation><mixed-citation xml:lang="en">Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. Journal of the American Academy of Dermatology 2004; 51:563–569, https://doi.org/10.1016/j.jaad.2004.04.012</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: A work in progress. Cutis 2018; 101:10–12.</mixed-citation><mixed-citation xml:lang="en">Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: A work in progress. Cutis 2018; 101:10–12.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wollina U, Tirant M, Vojvodic A, et al. Treatment of Psoriasis: Novel Approaches to Topical Delivery the Creative Commons AttributionNonCommercial 4.0 International License (CC BY-NC 4.0). Global Dermatology Open Access Maced J Med Sci 2019; 7:3018–3025 https://doi.org/10.3889/oamjms.2019.414</mixed-citation><mixed-citation xml:lang="en">Wollina U, Tirant M, Vojvodic A, et al. Treatment of Psoriasis: Novel Approaches to Topical Delivery the Creative Commons AttributionNonCommercial 4.0 International License (CC BY-NC 4.0). Global Dermatology Open Access Maced J Med Sci 2019; 7:3018–3025 https://doi.org/10.3889/oamjms.2019.414</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации по ведению больных псориазом. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», 2019 [Clinical guidelines for the management of patients with psoriasis. All-Russian Public Organization «Russian Society of Dermatovenereologists and Cosmetologists», 2019 (in Russ.)], https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf</mixed-citation><mixed-citation xml:lang="en">Клинические рекомендации по ведению больных псориазом. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», 2019 [Clinical guidelines for the management of patients with psoriasis. All-Russian Public Organization «Russian Society of Dermatovenereologists and Cosmetologists», 2019 (in Russ.)], https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Korman N, Korman N, Squibb B-M, et al. Management of psoriasis as a systemic disease: what is the evidence? Funding sources Conflicts of interest. British Journal of Dermatology Linked Comment: Gisondi Br J Dermatol 2020; 182:823–824, https://doi.org/10.1111/bjd.18245</mixed-citation><mixed-citation xml:lang="en">Korman N, Korman N, Squibb B-M, et al. Management of psoriasis as a systemic disease: what is the evidence? Funding sources Conflicts of interest. British Journal of Dermatology Linked Comment: Gisondi Br J Dermatol 2020; 182:823–824, https://doi.org/10.1111/bjd.18245</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. JDDG - Journal of the German Society of Dermatology 2018; 16:645–670, https://doi.org/10.1111/ddg.13516</mixed-citation><mixed-citation xml:lang="en">Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. JDDG - Journal of the German Society of Dermatology 2018; 16:645–670, https://doi.org/10.1111/ddg.13516</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 2008; 359:2195–2207, https://doi.org/10.1056/NEJMoa0807646</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 2008; 359:2195–2207, https://doi.org/10.1056/NEJMoa0807646</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Garshick MS, Drenkova K, Barrett TJ, et al. A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. Journal of Investigative Dermatology; 0. Epub ahead of print November 2021, https://doi.org/10.1016/J.JID.2021.07.190</mixed-citation><mixed-citation xml:lang="en">Garshick MS, Drenkova K, Barrett TJ, et al. A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. Journal of Investigative Dermatology; 0. Epub ahead of print November 2021, https://doi.org/10.1016/J.JID.2021.07.190</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Garshick MS, Ward NL, Krueger JG, et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology 2021; 77:1670–1680, https://doi.org/10.1016/j.jacc.2021.02.009</mixed-citation><mixed-citation xml:lang="en">Garshick MS, Ward NL, Krueger JG, et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology 2021; 77:1670–1680, https://doi.org/10.1016/j.jacc.2021.02.009</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mofarrah R, Mofarrah R, Amiri KJ. Beta-blocker bisoprolol induced psoriasis. Our Dermatology Online 2020; 11:59–61, https://doi.org/10.7241/ourd.20201.15</mixed-citation><mixed-citation xml:lang="en">Mofarrah R, Mofarrah R, Amiri KJ. Beta-blocker bisoprolol induced psoriasis. Our Dermatology Online 2020; 11:59–61, https://doi.org/10.7241/ourd.20201.15</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Milavec-Puretić V, Mance M, Čeović R, et al. Drug-Induced Psoriasis. American Journal of Clinical Dermatology 2012; 1:159–165, https://doi.org/10.2165/00128071-200001030-00003</mixed-citation><mixed-citation xml:lang="en">Milavec-Puretić V, Mance M, Čeović R, et al. Drug-Induced Psoriasis. American Journal of Clinical Dermatology 2012; 1:159–165, https://doi.org/10.2165/00128071-200001030-00003</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckland, NZ) 2017; 7:87–94, https://doi.org/10.2147/PTT.S126727</mixed-citation><mixed-citation xml:lang="en">Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckland, NZ) 2017; 7:87–94, https://doi.org/10.2147/PTT.S126727</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Puig L. Molecular Sciences Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci. 2018, 19(1):58, https://doi.org/10.3390/ijms19010058</mixed-citation><mixed-citation xml:lang="en">Puig L. Molecular Sciences Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci. 2018, 19(1):58, https://doi.org/10.3390/ijms19010058</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Burns DM. Epidemiology of smoking-induced cardiovascular disease. Progress in Cardiovascular Diseases 2003; 46:11–29, https://doi.org/10.1016/S0033-0620(03)00079-3</mixed-citation><mixed-citation xml:lang="en">Burns DM. Epidemiology of smoking-induced cardiovascular disease. Progress in Cardiovascular Diseases 2003; 46:11–29, https://doi.org/10.1016/S0033-0620(03)00079-3</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology 2019; 15:41–48, https://doi.org/10.1080/1744666X.2019.1543591</mixed-citation><mixed-citation xml:lang="en">Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology 2019; 15:41–48, https://doi.org/10.1080/1744666X.2019.1543591</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clinical Nutrition 2020; 39:1026–1040, https://doi.org/10.1016/j.clnu.2019.05.006</mixed-citation><mixed-citation xml:lang="en">Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clinical Nutrition 2020; 39:1026–1040, https://doi.org/10.1016/j.clnu.2019.05.006</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Norden A, Rekhtman S, Strunk A, et al. Risk of psoriasis according to body mass index: A retrospective cohort analysis. Journal of the American Academy of Dermatology 2021; 1–7, https://doi.org/10.1016/j.jaad.2021.06.012</mixed-citation><mixed-citation xml:lang="en">Norden A, Rekhtman S, Strunk A, et al. Risk of psoriasis according to body mass index: A retrospective cohort analysis. Journal of the American Academy of Dermatology 2021; 1–7, https://doi.org/10.1016/j.jaad.2021.06.012</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. European Journal of Preventive Cardiology 2019; 26:279–288, https://doi.org/10.1177/2047487318806658</mixed-citation><mixed-citation xml:lang="en">Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. European Journal of Preventive Cardiology 2019; 26:279–288, https://doi.org/10.1177/2047487318806658</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. Frontiers in Medicine 2021; 8: 1–7, https://doi.org/10.3389/fmed.2021.605691</mixed-citation><mixed-citation xml:lang="en">Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. Frontiers in Medicine 2021; 8: 1–7, https://doi.org/10.3389/fmed.2021.605691</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Aleem D, Tohid H. Pro-inflammatory Cytokines, Biomarkers, Genetics and the Immune System: A Mechanistic Approach of Depression and Psoriasis. Revista Colombiana de Psiquiatría 2018; 47:177–186,https://doi.org/10.1016/j.rcp.2017.03.002</mixed-citation><mixed-citation xml:lang="en">Aleem D, Tohid H. Pro-inflammatory Cytokines, Biomarkers, Genetics and the Immune System: A Mechanistic Approach of Depression and Psoriasis. Revista Colombiana de Psiquiatría 2018; 47:177–186,https://doi.org/10.1016/j.rcp.2017.03.002</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Collaboration S working group and EC risk, Achenbach S, Aleksandrova K, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021; Advance Article: 1–1, https://doi.org/10.1093/eurheartj/ehab309</mixed-citation><mixed-citation xml:lang="en">Collaboration S working group and EC risk, Achenbach S, Aleksandrova K, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021; Advance Article: 1–1, https://doi.org/10.1093/eurheartj/ehab309</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. The American journal of cardiology 2004; 94: 20–24, https://doi.org/10.1016/j.amjcard.2004.03.023</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. The American journal of cardiology 2004; 94: 20–24, https://doi.org/10.1016/j.amjcard.2004.03.023</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Baeta IGR, Gontijo B, Bittencourt FV, et al. Comorbidities and cardiovascular risk factors in patients with psoriasis. Anais Brasileiros de Dermatologia 2014; 89: 735–744, https://doi.org/10.1590/ABD1806-4841.20142874</mixed-citation><mixed-citation xml:lang="en">Baeta IGR, Gontijo B, Bittencourt FV, et al. Comorbidities and cardiovascular risk factors in patients with psoriasis. Anais Brasileiros de Dermatologia 2014; 89: 735–744, https://doi.org/10.1590/ABD1806-4841.20142874</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Barbieri JS, Beidas RS, Gondo GC, et al. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4467</mixed-citation><mixed-citation xml:lang="en">Barbieri JS, Beidas RS, Gondo GC, et al. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4467</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Garshick MS, Berger JS. Psoriasis and Cardiovascular Disease—An Ounce of Prevention Is Worth a Pound of Cure. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4723</mixed-citation><mixed-citation xml:lang="en">Garshick MS, Berger JS. Psoriasis and Cardiovascular Disease—An Ounce of Prevention Is Worth a Pound of Cure. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4723</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
